Get the Stockscreener App
60.67
0.05%
-0.0107
Incyte Corp stock is traded at $60.67, with a volume of 206.70K.
It is down -0.05% in the last 24 hours and down -17.48% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$60.68
Open:
$60.72
24h Volume:
206.70K
Relative Volume:
0.12
Market Cap:
$11.74B
Revenue:
$4.08B
Net Income/Loss:
$32.48M
P/E Ratio:
433.35
EPS:
0.14
Net Cash Flow:
$16.80M
1W Performance:
-2.05%
1M Performance:
-17.48%
6M Performance:
-7.87%
1Y Performance:
+6.46%
1-Day Range:
$60.35
$60.97
1-Week Range:
$60.24
$63.31
52-Week Range:
$50.35
$83.95
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
60.66 | 11.74B | 4.08B | 32.48M | 16.80M | 0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
498.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.43 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.15 | 36.26B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.32 | 34.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
268.31 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Incyte Announces Positive Phase 3 Results for Hidradenitis Suppurativa Treatment - MSN
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte Had a Bad Week. Investors Are Used to It. - MSN
Leerink Partners Adjusts Price Target on Incyte to $92 From $100, Maintains Outperform Rating - Marketscreener.com
Monday.com, Incyte, Lucid, Bloom, EQT: Trending by Analysts - TipRanks
Why Incyte Stock Was Tanking This Week - MSN
Incyte (INCY) Stock Declines Due to Clinical Trial Results - GuruFocus.com
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance
Incyte EVP Barry Flannelly sells $1.34 million in stock - Investing.com India
Stock market unimpressed by results for Incyte acne drug as share price drops 11% - delawarebusinessnow.com
Incyte price target lowered to $72 from $74 at Truist - Yahoo Finance
William Blair Downgrades Incyte (BMV:INCY) - Nasdaq
Incyte EVP Barry Flannelly sells $1.34 million in stock By Investing.com - Investing.com South Africa
William Blair Downgrades Incyte (BIT:1INCY) - Nasdaq
Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib (NASDAQ:INCY) - Seeking Alpha
Marginal Zone Lymphoma Pipeline 2025: MOA and ROA Insights, - openPR
INCY Stock Down on Disappointing Skin Disease Study Data - Yahoo Finance
Incyte stock price target cut to $72 at Truist Securities - Investing.com India
This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Incyte’s JAK1 blocker meets goals in Phase III trials - The Pharma Letter
Jefferies cuts Incyte stock price target to $75, keeps Buy rating - Investing.com
Mizuho maintains Incyte stock with $77 target, Neutral rating - Investing.com
Incyte divulges new MRGPRX2 antagonists - BioWorld Online
Citi maintains Buy on Incyte shares, reiterates $88 target - Investing.com
William Blair cuts Incyte stock rating post-trial results - Investing.com
Guggenheim Downgrades Incyte to Neutral From Buy -March 18, 2025 at 06:41 am EDT - Marketscreener.com
Analyst recommendations: Block, Incyte, Ralph Lauren, Five Below, Tesla... - Marketscreener.com
Deutsche Bank Adjusts Price Target on Incyte to $60 From $70, Keeps Hold Rating -March 18, 2025 at 05:50 am EDT - Marketscreener.com
Jefferies Adjusts Price Target on Incyte to $75 From $81, Keeps Buy Rating -March 18, 2025 at 05:50 am EDT - Marketscreener.com
Truist Securities Adjusts Price Target on Incyte to $72 From $74, Keeps Hold Rating -March 18, 2025 at 05:45 am EDT - Marketscreener.com
Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
William Blair Downgrades Incyte (INCY) to Market Perform - StreetInsider.com
Incyte stock dives after drug trial disappoints investors - Yahoo Finance
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
RBC maintains Incyte stock with $68 target post-data release By Investing.com - Investing.com Australia
Incyte stock tumbles despite meeting main goal in skin disease treatment trial - MSN
Incyte (INCY) Stock Drops on Phase Three Trial Data - GuruFocus.com
Why Incyte (INCY) Stock Is Nosediving - MSN
Leerink says Incyte’s povo trial results disappoint, drug likely to be approved - TipRanks
Oil pressures, Robinhood, Incyte: Market Minute - Yahoo Finance
Top Midday Decliners -March 17, 2025 at 02:00 pm EDT - Marketscreener.com
Incyte Reports Positive Results From Skin Therapy Study; Wells Fargo Cuts Price Target; Shares Drop - Marketscreener.com
Mizuho Reiterates Neutral Rating on Incyte (INCY) - StreetInsider.com
US MARKET Live, 17 March 2025: Incyte Corp, Tesla, and Dollar General among top losers on S&P 500 - Moneycontrol
Incyte stock hit by 11% despite paediatric dermatology trials hitting target - Yahoo Finance
Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results - MSN
Incyte stock hit 11% despite paediatric dermatology trials hitting target - Clinical Trials Arena
Incyte Leads S&P 500 Decliners Amidst Phase III Results of PovorcitinibNews and Statistics - IndexBox, Inc.
Top Stock Movers Now: Intel, Netflix, Incyte, and More - Yahoo Finance
Incyte Is Today’s Worst S&P 500 Stock. Here’s Why. - MSN
Nvidia, Netflix, Berkshire Hathaway, Baidu, Incyte, NCL, Affirm: Stocks to watch today - MSN
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):